Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2015 Publisher: King Pharmaceuticals Ltd, Donegal Street, Ballybofey, County Donegal, Ireland
Pharmacotherapeutic group: Antimycobacterials
ATC code: J04AB30
Capreomycin is active against human strains of Mycobacterium tuberculosis.
Capreomycin sulphate is not significantly absorbed from the gastrointestinal tract, and must be administered parenterally.
Following intramuscular injection of 1g of capreomycin in human subjects, peak serum concentrations in the range of 20-50µg/ml are achieved after 1-2 hours. Serum concentrations are low at 24 hours and daily injections of 1g for 30 days produced no significant accumulation in subjects with normal renal function.
Capreomycin is excreted in the urine, essentially unaltered, and approximately 50% of a 1g intramuscular dose is excreted within 12 hours.
There are no preclinical data of relevance to the prescriber in addition to those summarised in other sections of the Summary of Product Characteristics.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
